Find Clinical Trials
Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in non-depressed out-patients with severe Generalized Anxiety Disorder. A 12-week randomised, double-blind, versus escitalopram, 2-arm parallel groups, international multicenter study with a 9-month extension period
Servier Protocol Code:
CL3-20098-089
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2012-003699-37
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
Interventions / Treatments
The treatment(s) given to the participants in the study.
- Generalised Anxiety Disorder
- AGOMELATINE
- S020098
Other study id numbers
Other identification numbers the study may be known by.
- CL3-20098-089